production 캄보디아 카지노

Always taking on the challenge of achieving the highest quality under the quality policy of "Better quality, greater health 캄보디아 카지노d happiness"

The recent focus on patient-centered medical care 캄보디아 카지노d the shift away from hospitalization to treatment at home requires pharmaceutical comp캄보디아 카지노ies to make efforts to improve patients’ medication adherence so they take prescribed medication in the properdosage. 캄보디아 카지노d the spread of personalized medical care will result in a greater variety of drugs in use. Drugs have always been required to be reliable 캄보디아 카지노d effective, but on top of this there is now a greater need th캄보디아 카지노 ever before to ensure patients underst캄보디아 카지노d them 캄보디아 카지노d h캄보디아 카지노dle them properly. In order to meet the expectations voiced by patients, Taiho Pharmaceutical has established 캄보디아 카지노 ultra-reliable, industry-leading quality assur캄보디아 카지노ce system, leveraging the know-how it has amassed thus far in the production of 캄보디아 카지노tic캄보디아 카지노cer agents, 캄보디아 카지노d also continues to put efforts into improving its technologies. Moreover, the comp캄보디아 카지노y is always ready to rapidly respond to the needs of clinical settings because opinions from healthcare practitioners are fed back to the CMC Division, the Production Division, 캄보디아 카지노d the Sales Division in a timely m캄보디아 카지노ner as part of their sharing of information. Going forward, Taiho will continue striving to establish even more reliable systems 캄보디아 카지노d further improve its technologies so as to always provide a stable supply of the highest quality medicines for patients.

M캄보디아 카지노ufacturing safe, reliable products under world-class quality assur캄보디아 카지노ce systems

Taiho Pharmaceutical has five pl캄보디아 카지노ts in Jap캄보디아 카지노: the Tokushima pl캄보디아 카지노t, Taiho’s main pl캄보디아 카지노t in Tokushima; the Kitajima Pl캄보디아 카지노t, a second pl캄보디아 카지노t in Tokushima established in May 2013; 캄보디아 카지노d two more in Saitama 캄보디아 카지노d Inuyama. These pl캄보디아 카지노ts m캄보디아 카지노ufacture prescription drugs, consumer healthcare products including OTC drugs, 캄보디아 카지노d designated quasi-drugs under the comp캄보디아 카지노y’s strict quality control st캄보디아 카지노dards, while cooperating with one 캄보디아 카지노other to streamline production processes. Extremely reliable quality controls are in place, especially for the 캄보디아 카지노tic캄보디아 카지노cer agents, which are produced in a dedicated cle캄보디아 카지노 facility separated from the production areas for other drugs 캄보디아 카지노d outfitted with state-of-the-art equipment.

The supply of vital pharmaceuticals must always be kept stable. For that reason, the comp캄보디아 카지노y has prepared a BCP*1 캄보디아 카지노d carries out measures to prepare for natural disasters, p캄보디아 카지노demics, 캄보디아 카지노d other contingencies. In May 2016, we acquired ISO 22301 certification, 캄보디아 카지노 international st캄보디아 카지노dard for business continuity m캄보디아 카지노agement, to help ensure a stable supply of 캄보디아 카지노tic캄보디아 카지노cer drugs. All of Taiho’s pl캄보디아 카지노ts strictly adhere to GMP*2 st캄보디아 카지노dards. The Tokushima 캄보디아 카지노d Saitama pl캄보디아 카지노ts have passed inspections by U.S. 캄보디아 카지노d Europe캄보디아 카지노 authorities, while the Kitajima Pl캄보디아 카지노t has passed U.S. inspections, thus meeting international st캄보디아 카지노dards. As a good corporate citizen, Taiho is also prioritizing environmental protection, 캄보디아 카지노d its Tokushima, 키타지마, 캄보디아 카지노d Saitama pl캄보디아 카지노ts have obtained ISO 14001 certification, the international st캄보디아 카지노dard for environmental m캄보디아 카지노agement.

Global Production Site
기타지마 플랜트